symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
BYSI,1.03,0.101278,68701,40091823,0,0.542-3.45,0.01,BeyondSpring Inc.,USD,0001677940,KYG108301006,G10830100,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.beyondspringpharma.com,"BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.",Dr. Lan  Huang Ph.D.,Healthcare,US,73,646 305 6387,28 Liberty Street,New York,NY,10005,1.38823,2.43823,https://financialmodelingprep.com/image-stock/BYSI.png,2017-03-09,False,False,True,False,False
